Abstract

BackgroundThere is increasing global awareness and interest in the use of cannabis for therapeutic purposes (CTP). It is clear that health care professionals need to be involved in these decisions, but often lack the education needed to engage in informed discussions with patients. This study was conducted to determine the educational needs of Canadian physicians regarding CTP.MethodsA national needs assessment survey was developed based on previous survey tools. The survey was approved by the Research Ethics Board of the McGill University Health Centre Research Institute and was provided online using LimeSurvey®. Several national physician organizations and medical education organizations informed their members of the survey. The target audience was Canadian physicians. We sought to identify and rank using 5-point Likert scales the most common factors involved in decision making about using CTP in the following categories: knowledge, experience, attitudes, and barriers. Preferred educational approaches and physician demographics were collected. Gap analysis was conducted to determine the magnitude and importance of differences between perceived and desired knowledge on all decision factors.ResultsFour hundred and twenty six responses were received, and physician responses were distributed across Canada consistent with national physician distribution. The most desired knowledge concerned “potential risks of using CTP” and “safety, warning signs and precautions for patients using CTP”. The largest gap between perceived current and desired knowledge levels was “dosing” and “the development of treatment plans”.ConclusionsWe have identified several key educational needs among Canadian physicians regarding CTP. These data can be used to develop resources and educational programs to support clinicians in this area, as well as to guide further research to inform these gaps.

Highlights

  • There is increasing global awareness and interest in the use of cannabis for therapeutic purposes (CTP)

  • The new Marihuana for Medical Purposes Regulations (MMPR), which came into effect on 19 June 2013, completely replaced the Medical Marihuana Access Regulations (MMAR) on April

  • The MMPR maintains the physician’s pivotal role in patients’ access to CTP, despite concerns expressed by physicians about insufficient information on the risks and benefits of CTP, insufficient information regarding the appropriate use of CTP [3,4] and insufficient information with which to compare CTP with pharmaceutical cannabinoids

Read more

Summary

Introduction

There is increasing global awareness and interest in the use of cannabis for therapeutic purposes (CTP). This study was conducted to determine the educational needs of Canadian physicians regarding CTP. Canadian patients have had access to cannabis for therapeutic purposes (CTP) under Health Canada’s Medical Marihuana Access Program (MMAP) since 1999. The new Marihuana for Medical Purposes Regulations (MMPR), which came into effect on 19 June 2013, completely replaced the Medical Marihuana Access Regulations (MMAR) on April. Under the MMPR, patients may be authorised to possess herbal cannabis if they are issued a valid medical document from either a physician or a nurse practitioner; the medical document is not strictly speaking a ‘prescription’ as cannabis is not an approved drug, but it does contain information on daily ‘dose’ of cannabis (in grams/day) and duration of validity. The MMPR maintains the physician’s pivotal role in patients’ access to CTP, despite concerns expressed by physicians about insufficient information on the risks and benefits of CTP, insufficient information regarding the appropriate use of CTP [3,4] and insufficient information with which to compare CTP with pharmaceutical cannabinoids

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call